Eli Shareholders Equity Per Share from 2010 to 2024

LLY Stock  USD 777.77  11.09  1.45%   
Eli Lilly Shareholders Equity Per Share yearly trend continues to be fairly stable with very little volatility. Shareholders Equity Per Share will likely drop to 6.16 in 2024. During the period from 2010 to 2024, Eli Lilly Shareholders Equity Per Share regression line of annual values had r-squared of  0.05 and arithmetic mean of  10.31. View All Fundamentals
 
Shareholders Equity Per Share  
First Reported
2010-12-31
Previous Quarter
11.96637121
Current Value
6.16
Quarterly Volatility
4.20656252
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli main balance sheet or income statement drivers, such as Depreciation And Amortization of 994.5 M, Interest Expense of 327.9 M or Total Revenue of 35.8 B, as well as many exotic indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0074 or PTB Ratio of 51.15. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.
  
This module can also supplement Eli Lilly's financial leverage analysis and stock options assessment as well as various Eli Lilly Technical models . Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Shareholders Equity Per Share Growth Pattern

Below is the plot of the Shareholders Equity Per Share of Eli Lilly and over the last few years. It is Eli Lilly's Shareholders Equity Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.
Shareholders Equity Per Share10 Years Trend
Pretty Stable
   Shareholders Equity Per Share   
       Timeline  

Eli Shareholders Equity Per Share Regression Statistics

Arithmetic Mean10.31
Geometric Mean9.08
Coefficient Of Variation40.80
Mean Deviation3.34
Median11.81
Standard Deviation4.21
Sample Variance17.70
Range14.144
R-Value(0.21)
Mean Square Error18.19
R-Squared0.05
Significance0.45
Slope(0.20)
Total Sum of Squares247.73

Eli Shareholders Equity Per Share History

2024 6.16
2023 11.97
2022 11.81
2021 9.9
2020 6.22
2019 2.8
2018 9.56

About Eli Lilly Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Eli Lilly income statement, its balance sheet, and the statement of cash flows. Eli Lilly investors use historical funamental indicators, such as Eli Lilly's Shareholders Equity Per Share, to determine how well the company is positioned to perform in the future. Although Eli Lilly investors may use each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eli Lilly Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Shareholders Equity Per Share 11.97  6.16 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out the analysis of Eli Lilly Correlation against competitors.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.664
Dividend Share
4.69
Earnings Share
6.77
Revenue Per Share
39.919
Quarterly Revenue Growth
0.26
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.